-
公开(公告)号：US20230372520A1
公开(公告)日：2023-11-23
申请号：US18349438
申请日：2023-07-10
IPC分类号： A61K47/68 , A61K47/65 , A61K47/54 , A61P35/00 , A61K31/4745 , C07K16/30 , A61P35/02 , A61K39/395
CPC分类号： A61K47/6851 , A61K47/65 , A61K47/545 , A61K47/6803 , A61P35/00 , A61K31/4745 , C07K16/3092 , A61P35/02 , A61K39/39558 , A61K2039/505
摘要： The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
-
公开(公告)号：US09598476B2
公开(公告)日：2017-03-21
申请号：US14839222
申请日：2015-08-28
发明人： Gabriele Matschiner , Christine Rothe , Andreas Hohlbaum , Andrea Allersdorfer , Rachida Siham Bel Aiba , Marlon Hinner , Alexander Wiedenmann , Bradley Lunde , Shinji Yamaguchi , Takahide Aburatani , Ryuji Hashimoto , Tohru Takahashi , Chikako Nagasaki , Futoshi Nara , Tomohiro Nishizawa
IPC分类号： C07K14/47 , G01N33/573 , A61K39/00 , C07K14/435
CPC分类号： A61K38/1709 , A61K39/00 , A61K47/54 , A61K47/58 , A61K47/64 , A61K2121/00 , C07K14/435 , C07K14/47 , G01N33/573
摘要： The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
-
公开(公告)号：US20160024161A1
公开(公告)日：2016-01-28
申请号：US14839222
申请日：2015-08-28
发明人： Gabriele MATSCHINER , Christine Rothe , Andreas Hohlbaum , Andrea Allersdorfer , Rachida Siham Bel Aiba , Marlon Hinner , Alexander Wiedenmann , Bradley Lunde , Shinji Yamaguchi , Takahide Aburatani , Ryuji Hashimoto , Tohru Takahashi , Chikako Nagasaki , Futoshi Nara , Tomohiro Nishizawa
IPC分类号： C07K14/47
CPC分类号： A61K38/1709 , A61K39/00 , A61K47/54 , A61K47/58 , A61K47/64 , A61K2121/00 , C07K14/435 , C07K14/47 , G01N33/573
摘要： The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
摘要翻译： 本公开内容涉及结合PCSK9的新型脂质运载蛋白突变蛋白。 本公开还提供了相应的编码脂质运载蛋白突变蛋白的核酸分子以及用于产生脂质运载蛋白突变蛋白及其编码核酸分子的方法。
-
公开(公告)号：US20150079114A1
公开(公告)日：2015-03-19
申请号：US14389959
申请日：2013-04-23
发明人： Toshiaki Ohtsuka , Kimihisa Ichikawa , Ayumi Yada
CPC分类号： C07K16/2878 , A61K47/6803 , A61K47/6851
摘要： Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups andor spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody.
摘要翻译： 配体药物缀合物具有通过连接基团和隔离物连接的DRS结合部分与有效治疗各种癌症的治疗剂。 在一些实施方案中，配体药物缀合物具有下式：L-（LU-D）p，其中L是配体单元，LU是连接子单元，D是药物单位（或细胞毒性剂）。 下标p是1至20的整数。因此，配体药物缀合物包含与至少一个药物单元共价连接的配体单元。 药物单位可以直接或通过链接单元（-LU-）共价连接。 配体单元是DR5结合剂，例如抗DRS抗体。
-
公开(公告)号：US11872289B2
公开(公告)日：2024-01-16
申请号：US17878611
申请日：2022-08-01
IPC分类号： A61K47/68 , A61K47/65 , A61K47/54 , A61P35/00 , A61K31/4745 , C07K16/30 , A61P35/02 , A61K39/395 , A61K39/00
CPC分类号： A61K47/6851 , A61K31/4745 , A61K39/39558 , A61K47/545 , A61K47/65 , A61K47/6803 , A61P35/00 , A61P35/02 , C07K16/3092 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
-
公开(公告)号：US11840736B2
公开(公告)日：2023-12-12
申请号：US16547434
申请日：2019-08-21
发明人： Matthias Schneider , Sabine Blum , Renee Jeanne Mendell-Harary , Daniel J. Freeman , Robert Allen Beckman , Xiaoping Jin
IPC分类号： G01N33/574 , A61K39/395 , C12Q1/6886 , C07K16/32 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： C12Q1/6886 , A61K39/39558 , A61K45/06 , C07K16/2863 , C07K16/32 , A61K2039/505 , C07K2317/73 , C12Q2600/106 , C12Q2600/158 , G01N2333/4704
摘要： The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
-
公开(公告)号：US20170166615A1
公开(公告)日：2017-06-15
申请号：US15371698
申请日：2016-12-07
发明人： GABRIELE MATSCHINER , Christine ROTHE , Alexander WIEDENMANN , Rachida Siham BEL AIBA , Marlon HINNER , Andrea ALLERSDORFER , Bradley LUNDE , Kazufumi KUBOTA , Mitsuhiro MAKINO , Sakiko TAKAHASHI , Ryuji HASHIMOTO , Tohru TAKAHASHI , Mamoru OTOYO
IPC分类号： C07K14/47
摘要： The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins
-
公开(公告)号：US20240043939A1
公开(公告)日：2024-02-08
申请号：US18380117
申请日：2023-10-13
发明人： Matthias SCHNEIDER , Sabine BLUM , Renee Jeanne MENDELL-HARARY , Daniel J. FREEMAN , Robert Allen BECKMAN , Xiaoping JIN
IPC分类号： C12Q1/6886 , C07K16/32 , C07K16/28 , A61K39/395 , A61K45/06
CPC分类号： C12Q1/6886 , C07K16/32 , C07K16/2863 , A61K39/39558 , A61K45/06 , A61K2039/505
摘要： The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
-
公开(公告)号：US20230139769A1
公开(公告)日：2023-05-04
申请号：US17878611
申请日：2022-08-01
IPC分类号： A61K47/68 , A61K47/65 , A61K47/54 , A61P35/00 , A61K31/4745 , C07K16/30 , A61P35/02 , A61K39/395
摘要： The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
-
公开(公告)号：US20210187118A1
公开(公告)日：2021-06-24
申请号：US17055323
申请日：2019-05-17
摘要： The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.023 秒)
